iifl-logo

Biocon Ltd Board Meeting

340.65
(2.45%)
May 21, 2025|12:00:00 AM

Biocon CORPORATE ACTIONS

21/05/2024calendar-icon
21/05/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting8 May 20252 Apr 2025
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/05/2025 inter alia to consider and approve Board Meeting Intimation Financial Results for the Quarter and Year ended March 31, 2025 Recommended a final dividend at the rate of 10% i.e. Re. 0.50/- per equity share of face value of Rs. 5/- each for the financial year ended March 31, 2025, subject to Shareholders approval at the ensuing Annual General Meeting (AGM). Pursuant to Regulation 42 of SEBI Listing Regulations, the Company has fixed Friday, July 04, 2025 as the record date for determining entitlement of Members to final dividend for the financial year ended March 31, 2025. The dividend will be paid on or before September 05, 2025. (As Per BSE Announcement Dated on :08.05.2025)
Board Meeting23 Apr 202520 Apr 2025
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/04/2025 inter alia to consider and approve To consider and approve the proposal for raising of funds by way of issue of equity shares or any other eligible securities through one or more of the permissible modes including but not limited to qualified institutions placement rights issue preferential issue further public offer etc. Outcome of Board Meeting (As Per Bse Announcement Dated on :23.04.2025)
Board Meeting4 Apr 20251 Apr 2025
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/04/2025 inter alia to consider and approve Intimation of Board meeting for raising funds through issuance of Commercial Papers or through any other mode Issuance of Commercial Papers up to an amount not exceeding Rs. 600 Crores in one or more tranches on private placement basis (As Per Bse Announcement Dated on 04.04.2025)
Board Meeting30 Jan 20253 Jan 2025
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2024 amongst other routine matters. Outcome of Board Meeting dated 30.01.2025 (As Per Bse Announcement Dated on 30.01.2025)
Board Meeting27 Jan 202522 Jan 2025
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 ,inter alia, to consider and approve Raising of Funds through issuance of Commercial Papers (CPs) or through any other mode on private placement basis. Outcome of Board Meeting held on 27.01.2025 (As Per BSE Announcement Dated on 27/01/2025)
Board Meeting30 Oct 20243 Oct 2024
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2024 inter alia to consider and approve Intimation for board meeting Unaudited Standalone and Consolidated Financial Results for quarter and half-year ended September 30, 2024 Outcome of Board Meeting dated October 30, 2024 (As Per BSE Announcement dated on 30.10.2024)
Board Meeting8 Aug 202417 Jul 2024
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve approval of the un-audited financial results for the quarter ended 30.06.2024. Outcome of the Board Meeting held on 08.08.2024 (As Per BSE Announcement Dated on: 08/08/2024)
Board Meeting11 Jun 202411 Jun 2024
Appointment of Interim CFO

Biocon: Related News

Biocon shares zoom ~2% after drug launch in Japan
21 May 2025|11:41 AM

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

Read More
Biocon Q4 Net Profit Soars 154% YoY to ₹344.5 Crore
11 May 2025|08:59 AM

The operating performance was also good as EBITDA increased 17.7% to ₹1,078.2 crore in March quarter compared with ₹915.9 crore in Q4 FY24.

Read More
Biocon Biologics Secures Multiple Market Access for Yesintek
5 May 2025|03:48 PM

Yesintek has been added to Express Scripts' National Preferred Formulary (NPF), effective March 21, 2025.

Read More
Biocon to Raise ₹4,500 Crore; Approves Capital Expansion Plan
24 Apr 2025|09:50 PM

The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.

Read More
Top Stocks for Today - 24th April 2025
24 Apr 2025|06:20 AM

Here are some of the stocks that may see significant price movement today: LTIMindtree, Dalmia Bharat, Bajaj Housing, etc.

Read More
Biocon unit expands oncology portfolio after USFDA approval
11 Apr 2025|09:00 AM

Jobevne is a vascular endothelial growth factor (VEGF) impediment that sticks with VEGF and restrain the interaction with its receptors.

Read More
Biocon Pharma Gains USFDA Approval for Norepinephrine and Key Therapies
24 Mar 2025|11:51 PM

The first approval is for the 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths of Lenalidomide Capsules.

Read More
Biocon Biologics inks pact with Civica to expand access in US
7 Mar 2025|08:53 AM

Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.

Read More
Biocon Secures USFDA Approval for Dasatinib
5 Mar 2025|01:40 PM

The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults who have shown resistance or intolerance to prior therapy.

Read More
Biocon launches generic Liraglutide in the UK
28 Feb 2025|01:53 PM

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.